FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4367048265> ?p ?o ?g. }

• W4367048265 endingPage "728" @default.
• W4367048265 startingPage "728" @default.
• W4367048265 abstract "Importance It is not clear which severely injured patients with hemorrhagic shock may benefit most from a 1:1:1 vs 1:1:2 (plasma:platelets:red blood cells) resuscitation strategy. Identification of trauma molecular endotypes may reveal subgroups of patients with differential treatment response to various resuscitation strategies. Objective To derive trauma endotypes (TEs) from molecular data and determine whether these endotypes are associated with mortality and differential treatment response to 1:1:1 vs 1:1:2 resuscitation strategies. Design, Setting, and Participants This was a secondary analysis of the Pragmatic, Randomized Optimal Platelet and Plasma Ratios (PROPPR) randomized clinical trial. The study cohort included individuals with severe injury from 12 North American trauma centers. The cohort was taken from the participants in the PROPPR trial who had complete plasma biomarker data available. Study data were analyzed on August 2, 2021, to October 25, 2022. Exposures TEs identified by K-means clustering of plasma biomarkers collected at hospital arrival. Main Outcomes and Measures An association between TEs and 30-day mortality was tested using multivariable relative risk (RR) regression adjusting for age, sex, trauma center, mechanism of injury, and injury severity score (ISS). Differential treatment response to transfusion strategy was assessed using an RR regression model for 30-day mortality by incorporating an interaction term for the product of endotype and treatment group adjusting for age, sex, trauma center, mechanism of injury, and ISS. Results A total of 478 participants (median [IQR] age, 34.5 [25-51] years; 384 male [80%]) of the 680 participants in the PROPPR trial were included in this study analysis. A 2-class model that had optimal performance in K-means clustering was found. TE-1 (n = 270) was characterized by higher plasma concentrations of inflammatory biomarkers (eg, interleukin 8 and tumor necrosis factor α) and significantly higher 30-day mortality compared with TE-2 (n = 208). There was a significant interaction between treatment arm and TE for 30-day mortality. Mortality in TE-1 was 28.6% with 1:1:2 treatment vs 32.6% with 1:1:1 treatment, whereas mortality in TE-2 was 24.5% with 1:1:2 treatment vs 7.3% with 1:1:1 treatment ( P for interaction = .001). Conclusions and Relevance Results of this secondary analysis suggest that endotypes derived from plasma biomarkers in trauma patients at hospital arrival were associated with a differential response to 1:1:1 vs 1:1:2 resuscitation strategies in trauma patients with severe injury. These findings support the concept of molecular heterogeneity in critically ill trauma populations and have implications for tailoring therapy for patients at high risk for adverse outcomes." @default.
• W4367048265 created "2023-04-27" @default.
• W4367048265 creator A5001233740 @default.
• W4367048265 creator A5005611041 @default.
• W4367048265 creator A5008530627 @default.
• W4367048265 creator A5009832906 @default.
• W4367048265 creator A5021432201 @default.
• W4367048265 creator A5025213353 @default.
• W4367048265 creator A5044405868 @default.
• W4367048265 creator A5045934923 @default.
• W4367048265 creator A5049570322 @default.
• W4367048265 creator A5051171682 @default.
• W4367048265 creator A5051687396 @default.
• W4367048265 creator A5056060130 @default.
• W4367048265 creator A5072168670 @default.
• W4367048265 creator A5076303643 @default.
• W4367048265 creator A5089504452 @default.
• W4367048265 date "2023-07-01" @default.
• W4367048265 modified "2023-10-10" @default.
• W4367048265 title "Association of Trauma Molecular Endotypes With Differential Response to Transfusion Resuscitation Strategies" @default.
• W4367048265 cites W1967433109 @default.
• W4367048265 cites W1987971958 @default.
• W4367048265 cites W1996881001 @default.
• W4367048265 cites W2004195549 @default.
• W4367048265 cites W2029587171 @default.
• W4367048265 cites W2033971296 @default.
• W4367048265 cites W2061771240 @default.
• W4367048265 cites W2067123175 @default.
• W4367048265 cites W2077804279 @default.
• W4367048265 cites W2083005745 @default.
• W4367048265 cites W2097364950 @default.
• W4367048265 cites W2107926882 @default.
• W4367048265 cites W2124519382 @default.
• W4367048265 cites W2133226878 @default.
• W4367048265 cites W2465411673 @default.
• W4367048265 cites W2471841324 @default.
• W4367048265 cites W2515625652 @default.
• W4367048265 cites W2561982390 @default.
• W4367048265 cites W2731942961 @default.
• W4367048265 cites W2765836795 @default.
• W4367048265 cites W2883181532 @default.
• W4367048265 cites W2885500852 @default.
• W4367048265 cites W2896434545 @default.
• W4367048265 cites W2898483928 @default.
• W4367048265 cites W2944988359 @default.
• W4367048265 cites W3013413227 @default.
• W4367048265 cites W3080981445 @default.
• W4367048265 cites W3102547229 @default.
• W4367048265 cites W3193155969 @default.
• W4367048265 cites W3210954766 @default.
• W4367048265 cites W3217158931 @default.
• W4367048265 cites W4231141634 @default.
• W4367048265 cites W4235283192 @default.
• W4367048265 cites W4244287538 @default.
• W4367048265 cites W4293108385 @default.
• W4367048265 cites W4376596080 @default.
• W4367048265 doi "https://doi.org/10.1001/jamasurg.2023.0819" @default.
• W4367048265 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37099286" @default.
• W4367048265 hasPublicationYear "2023" @default.
• W4367048265 type Work @default.
• W4367048265 citedByCount "2" @default.
• W4367048265 countsByYear W43670482652023 @default.
• W4367048265 crossrefType "journal-article" @default.
• W4367048265 hasAuthorship W4367048265A5001233740 @default.
• W4367048265 hasAuthorship W4367048265A5005611041 @default.
• W4367048265 hasAuthorship W4367048265A5008530627 @default.
• W4367048265 hasAuthorship W4367048265A5009832906 @default.
• W4367048265 hasAuthorship W4367048265A5021432201 @default.
• W4367048265 hasAuthorship W4367048265A5025213353 @default.
• W4367048265 hasAuthorship W4367048265A5044405868 @default.
• W4367048265 hasAuthorship W4367048265A5045934923 @default.
• W4367048265 hasAuthorship W4367048265A5049570322 @default.
• W4367048265 hasAuthorship W4367048265A5051171682 @default.
• W4367048265 hasAuthorship W4367048265A5051687396 @default.
• W4367048265 hasAuthorship W4367048265A5056060130 @default.
• W4367048265 hasAuthorship W4367048265A5072168670 @default.
• W4367048265 hasAuthorship W4367048265A5076303643 @default.
• W4367048265 hasAuthorship W4367048265A5089504452 @default.
• W4367048265 hasConcept C105698618 @default.
• W4367048265 hasConcept C126322002 @default.
• W4367048265 hasConcept C141071460 @default.
• W4367048265 hasConcept C167135981 @default.
• W4367048265 hasConcept C168563851 @default.
• W4367048265 hasConcept C177713679 @default.
• W4367048265 hasConcept C190385971 @default.
• W4367048265 hasConcept C194828623 @default.
• W4367048265 hasConcept C2777298740 @default.
• W4367048265 hasConcept C2778165595 @default.
• W4367048265 hasConcept C2780110798 @default.
• W4367048265 hasConcept C3017944768 @default.
• W4367048265 hasConcept C44249647 @default.
• W4367048265 hasConcept C71924100 @default.
• W4367048265 hasConcept C72563966 @default.
• W4367048265 hasConcept C82789193 @default.
• W4367048265 hasConcept C85004164 @default.
• W4367048265 hasConceptScore W4367048265C105698618 @default.
• W4367048265 hasConceptScore W4367048265C126322002 @default.
• W4367048265 hasConceptScore W4367048265C141071460 @default.

• next